Mikko Siurala
Head of Preclinical Science
Pharmaceutical Sciences
TILT Biotherapeutics
Finland
Biography
Trained in genetics and molecular biology, Mr Siurala worked for 5 years at the EMBL affiliated Institute for Molecular Medicine Finland (FIMM). He then became interested in oncolytic viruses and joined the Cancer Gene Therapy Group at the University of Helsinki, finishing his PhD in January 2017. Believing in the utility of oncolytic viruses for enhancing T-cell therapies, he joined TILT in November 2013, and now heads the preclinical activities of TILT.
Research Interest
Pharmaceutical Sciences
